Loading stock data…
Harrow (HROW)
$41.15-0.92 (-2.19%)
After Hours$41.15+0.00 (+0.00%)· Last close Jun 29
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harrow, Inc. in the Healthcare sector is trading at $41.15 with a market capitalization of $1.4B. Wall Street consensus targets $67.75 (8 analysts), implying a +64.6% move over the next 12 months. The stock is currently 25% below its 52-week high of $54.85, remaining 0.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 78 is overbought against a weak tape. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +64.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 78 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.20M↓ | $89.09M↑ | $71.64M↑ | $63.74M↑ | $47.83M |
| Gross Profit | $27.05M↓ | $70.62M↑ | $53.93M↑ | $47.51M↑ | $32.31M |
| Operating Income | -$22.08M↓ | $15.59M↑ | $14.75M↑ | $11.41M↑ | -$11.23M |
| Net Income | -$27.60M↓ | $6.63M↑ | $1.02M↓ | $5.00M↑ | -$17.78M |
Peer Comparison
JNJUNHPFE
Fundamentals
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers Imprimis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.12%
Volume
Today's trading volume
473,666
Recent News
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental […]
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on TopSecretStocks’s Substack by Simon. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.’s share was trading at $33.10 as of June 8th. HROW’s trailing and forward P/E were 9.64 and 232.56 respectively according to Yahoo Finance. […]
Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?
In June 2026, Harrow announced the re-launch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, an FDA-approved, steroid-sparing therapy for vernal keratoconjunctivitis (VKC) in children and adults, backed by a broader push on physician education, patient access, and affordability. This move directly targets a historically under-served pediatric VKC population where many patients remain poorly controlled on antihistamines and face long-term steroid safety concerns, potentially reshaping...
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?
Harrow, Inc. (NASDAQ:HROW) is one of the top small cap stocks with huge growth potential. On May 13, Cantor Fitzgerald analyst Steve Seedhouse lowered his price target on Harrow, Inc. (NASDAQ:HROW) from $91 to $88, while keeping his Overweight rating intact. The analyst made the move in response to Harrow’s downward revision to its near-term […]
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Harrow, Inc. (NASDAQ:HROW) is one of the best pharma stocks. TheFly reported on May 14 that HROW had its price target reduced by B.Riley to $60 from $65 while a Buy rating was maintained. The update followed first-quarter […]